All In Biotech

Drug Trial Radar · NCT06941350

A Trial to Evaluate the Safety and Efficacy of NCR102 in Subjects With aGVHD

A Phase I/II Clinical Study Evaluating the Safety and Efficacy of NCR102 Injection in the Treatment of Acute Graft-versus-Host Disease (aGVHD)

Last checked: Nov 19, 2026Latest source record: Apr 23, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

24

Planned (sponsor's estimate)

Start

Apr 28, 2025

Primary completion

Oct 30, 2026

Study completion May 30, 2027

Sponsor

Sponsor type
Industry
First posted
Apr 23, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Evaluate the safety and efficacy of NCR102 injection in the treatment of SR-aGVHD patients who have failed second-line therapy.

Conditions

  • Acute Graft-versus-Host Disease

Interventions

  • NCR102 injectionBiological

    Twice a week for 4 weeks, and the treatment continues for another 4 weeks in subjects with partial remission by day 28.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Adverse Event(AE) or Serious Adverse Event(SAE)Time frame: 100 days after first administration of NCR102 injection

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.